| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 3.7K | 0.3% | 0.3% |
| Total Income | 3.7K | 0.3% | 0.3% |
| Expenditure | 3.5K | 7.1% | 2.7% |
| PBT | 127.90 | 299.8% | 1719.0% |
| Net Profit | -325.30 | 173.8% | 153.7% |
| OPM | 7.00% | 6.83pp | 2.23pp |
| NPM | -8.71% | 5.54pp | 5.29pp |
| EPS | -0.28 | 180.0% | 154.6% |
Viatris Reports Third-Quarter 2026 Financial Results
05 Nov 2026 · 5 Nov, 6:21 pm
Summary
Viatris reported third-quarter 2026 total revenues of $3.75 billion, which remained essentially flat year-over-year due to a mix of factors including new product sales and strong performance in Greater China offsetting supply constraints and competition. The company posted a U.S. GAAP net loss of $325 million, widening from the previous year, primarily due to an increase in income tax provision. However, adjusted EBITDA rose 4% to $1.20 billion and adjusted EPS increased 6% to $0.71, reflecting strong operational momentum and cost discipline. Management expressed confidence in the growth trajectory and raised 2026 financial guidance midpoints across all key metrics.
Key Highlights
- 1
Viatris reported total revenues of $3.75 billion for the third quarter of 2026, which were essentially flat on both a reported and operational basis compared to the prior year.
- 2
The company delivered a U.S. GAAP net loss of $325 million for Q3 2026, compared to a net loss of $128 million in the same period of 2025.
- 3
Adjusted EBITDA for the third quarter of 2026 was $1.20 billion, up 4% on a reported basis and 1% on an operational basis compared to Q3 2025.
- 4
Adjusted EPS was $0.71 per share, up 6% on a reported basis and 3% on an operational basis compared to the third quarter of 2025.
- 5
The company generated $899 million in U.S. GAAP net cash provided by operating activities for Q3 2026, a 21% increase year-over-year.
- 6
Viatris is raising its 2026 financial guidance midpoints for all key metrics, including total revenues, Adjusted EBITDA, Adjusted EPS, and Free Cash Flow.
- 7
The company received regulatory approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan, and advanced its innovative medicines strategy with the planned acquisition of Pacira BioSciences.
Management Comments
Scott A. Smith
Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business. Momentum across key areas of our base business, progress in our pipeline and the benefits of our enterprise-wide strategic review continue to strengthen our company. With the recent U.S. launch of Gwyn Lo, approvals of RYZUMVI in the U.S. and WAKIX in Japan, the potential upcoming approval and launch of fast-acting meloxicam and our recently announced agreement to acquire Pacira BioSciences, we are taking important steps to position Viatris for sustained revenue and earnings growth.
Paul Campbell
We are very pleased with the operational momentum across our higher-margin businesses and continued focus on cost discipline, which led to strong overall third-quarter results. Based on this performance and our confidence in the outlook for the rest of the year, we are once again raising the midpoints of our financial guidance ranges across all key metrics. Also, consistent with our disciplined and balanced capital allocation strategy, we continued returning additional value to shareholders in the quarter and expect the Pacira transaction to have minimal impact on our gross leverage ratio upon expected closing by the end of November.
Informational and educational content only. Not investment advice.